Xilio Therapeutics, Inc.XLONASDAQ
Loading
EBITDA Margin Over TimeExpanding
Percentile Rank17
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-95.92%
↑ 34% vs avg
Percentile
P17
Within normal range
Streak
1 yr
Consecutive growthExpanding
Average
-144.31%
Historical baseline
PeriodValueYoY Change
2025-95.92%+89.5%
2024-914.27%-
20230.00%-
20220.00%-
20210.00%-
20200.00%-
20190.00%-